Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Ocular biometry, refraction and time spent outdoors during daylight in Irish schoolchildren.

Harrington SC, O'Dwyer V.

Clin Exp Optom. 2019 Jun 11. doi: 10.1111/cxo.12929. [Epub ahead of print]

PMID:
31187504
2.

Risk factors associated with myopia in schoolchildren in Ireland.

Harrington SC, Stack J, O'Dwyer V.

Br J Ophthalmol. 2019 Feb 11. pii: bjophthalmol-2018-313325. doi: 10.1136/bjophthalmol-2018-313325. [Epub ahead of print]

PMID:
30745305
3.

Refractive error and visual impairment in Ireland schoolchildren.

Harrington SC, Stack J, Saunders K, O'Dwyer V.

Br J Ophthalmol. 2019 Aug;103(8):1112-1118. doi: 10.1136/bjophthalmol-2018-312573. Epub 2018 Oct 12.

4.

Systematic Bias Introduced by Genomic DNA Template Dilution in 16S rRNA Gene-Targeted Microbiota Profiling in Human Stool Homogenates.

Multinu F, Harrington SC, Chen J, Jeraldo PR, Johnson S, Chia N, Walther-Antonio MR.

mSphere. 2018 Mar 14;3(2). pii: e00560-17. doi: 10.1128/mSphere.00560-17. eCollection 2018 Mar-Apr.

5.

A comprehensive analysis of breast cancer microbiota and host gene expression.

Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC, Suman VJ, Wang L, Weinshilboum RL, Boughey JC, Kocher JP, Nelson H, Goetz MP, Kalari KR.

PLoS One. 2017 Nov 30;12(11):e0188873. doi: 10.1371/journal.pone.0188873. eCollection 2017.

6.

Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome.

Valentin N, Camilleri M, Carlson P, Harrington SC, Eckert D, O'Neill J, Burton D, Chen J, Shaw AL, Acosta A.

Physiol Rep. 2017 Mar;5(5). pii: e13170. doi: 10.14814/phy2.13170.

7.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.

8.

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.

Becker MA, Hou X, Tienchaianada P, Haines BB, Harrington SC, Weroha SJ, Sathyanarayanan S, Haluska P.

BMC Cancer. 2016 Oct 20;16(1):814.

9.

Shifts in the Fecal Microbiota Associated with Adenomatous Polyps.

Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, Nelson H, Boardman LA, Druliner BR, Levin TR, Rex DK, Ahnen DJ, Lance P, Ahlquist DA, Chia N.

Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):85-94. doi: 10.1158/1055-9965.EPI-16-0337. Epub 2016 Sep 26.

10.

Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.

Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P.

PLoS One. 2015 May 11;10(5):e0126867. doi: 10.1371/journal.pone.0126867. eCollection 2015.

11.

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P.

Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611. Epub 2014 Jan 7.

12.

Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.

Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P.

Mol Cancer Ther. 2013 Dec;12(12):2909-16. doi: 10.1158/1535-7163.MCT-13-0547. Epub 2013 Oct 15.

13.

Quantifying insulin receptor isoform expression in FFPE breast tumors.

Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P.

Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):108-15. doi: 10.1016/j.ghir.2012.04.001. Epub 2012 Apr 30.

14.

IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.

Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM, Haluska P.

Clin Cancer Res. 2012 Mar 15;18(6):1808-17. doi: 10.1158/1078-0432.CCR-11-1806. Epub 2012 Jan 27.

15.

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, Finckenstein FG, Brodie A, Gottardis MM, Carboni JM, Haluska P.

Cancer Res. 2011 Dec 15;71(24):7597-607. doi: 10.1158/0008-5472.CAN-11-1080. Epub 2011 Oct 31.

16.

Transgenic overexpression of pregnancy-associated plasma protein-A in murine arterial smooth muscle accelerates atherosclerotic lesion development.

Conover CA, Mason MA, Bale LK, Harrington SC, Nyegaard M, Oxvig C, Overgaard MT.

Am J Physiol Heart Circ Physiol. 2010 Aug;299(2):H284-91. doi: 10.1152/ajpheart.00904.2009. Epub 2010 May 14.

17.

Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.

Miedema MD, Conover CA, MacDonald H, Harrington SC, Oberg D, Wilson D, Henry TD, Schwartz RS.

Am J Cardiol. 2008 Jan 1;101(1):35-9.

PMID:
18157962
18.

Differential regulation of pregnancy associated plasma protein-A in human coronary artery endothelial cells and smooth muscle cells.

Conover CA, Harrington SC, Bale LK.

Growth Horm IGF Res. 2008 Jun;18(3):213-20. Epub 2007 Oct 23.

20.

Surface association of pregnancy-associated plasma protein-A accounts for its colocalization with activated macrophages.

Conover CA, Harrington SC, Bale LK, Oxvig C.

Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H994-H1000. Epub 2006 Oct 13.

21.

Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol.

Conover CA, Bale LK, Harrington SC, Resch ZT, Overgaard MT, Oxvig C.

Am J Physiol Cell Physiol. 2006 Jan;290(1):C183-8.

Supplemental Content

Loading ...
Support Center